维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

1篇 您的检索式：作者名="Paroma Deb"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	An update to monoclonal antibody as therapeutic option against COVID-19显示文摘With the number of Coronavirus Disease 2019(COVID-19)cases soaring worldwide and limited vaccine availability for the general population in most countries,the monoclonal antibody(mAb)remains a viable therapeutic option to treat COVID-19 disease and its complications,especially in the elderly individuals.More than 50 monoclonal antibody-related clinical trials are being conducted in different countries around the world,with few of them nearing the completion of the third and fourth phase clinical trial.In view of recent emergency use authorization(EUA)from the FDA(Food and Drug Administration)of casirivimab and imdevimab,it is of importance thatmAbs,already used to treat diseases such as Ebola and respiratory syncytial virus(RSV)infection,are discussed in scientific communities.This brief review discusses the mechanism of action and updates to clinical trials of different monoclonal antibodies used to treat COVID-19,with special attention paid to SARS-CoV-2 immune response in host cells,target viral structures,and justification of developing mAbs following the approval and administration of potential effective vaccine among vulnerable populations in different countries.	Paroma Deb Md.Maruf Ahmed Molla K.M.Saif-Ur-Rahman	2021	Biosafety and Health2021，3，2：	2

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费